Prime Medicine Stock Forecast

Stock Price Forecast

According to 13 analysts polled by S&P Global, Prime Medicine stock has a consensus rating of "Buy" and an average price target of $6.92. The average 1-year stock price forecast is 134.18% higher than the current stock price, while the lowest is $4.25 (+43.82%) and the highest is $11 (+272.25%).

Price Target: $6.92 (+134.18%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$4.25	$6.92	$6.00	$11
Change	+43.82%	+134.18%	+103.05%	+272.25%

Analyst Ratings

The average analyst rating for Prime Medicine stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26	May '26
Strong Buy	7	6	6	8	8	8
Buy	1	1	1	1	1	1
Hold	4	4	4	4	4	4
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	12	11	11	13	13	13

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Terence Flynn Morgan Stanley	Morgan Stanley	Hold Maintains n/a	Hold	Maintains	n/a	n/a	May 13, 2026
Kostas Biliouris Oppenheimer	Oppenheimer	Buy Reiterates $11	Buy	Reiterates	$11	+272.25%	May 12, 2026
Boris Peaker JonesTrading	JonesTrading	Buy Reiterates $5	Buy	Reiterates	$5	+69.20%	May 8, 2026
Geulah Livshits Chardan Capital	Chardan Capital	Buy Reiterates $9	Buy	Reiterates	$9	+204.57%	May 8, 2026
Unknown Analyst Wedbush No rating	Wedbush	Buy Maintains $8	Buy	Maintains	$8	+170.73%	May 8, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

12.93M

from 4.63M

179.05%

from 4.63M

Revenue Next Year

22.52M

from 12.93M

74.19%

from 12.93M

EPS This Year

-0.98

from -1.35

EPS Next Year

-0.87

from -0.98

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-	-	2.98M	4.63M	12.93M
Revenue Growth	-	-	-	-	55.28%	179.05%
Gross Profit	-70.55M	-86.73M	-147.91M	-152.31M	-156.00M	12.93M
Gross Margin	-	-	-	-5,105.80%	-3,367.96%	100.00%
Operating Income	-84.47M	-116.54M	-191.29M	-202.47M	-208.35M	-191.72M
Net Income	-165.37M	-121.82M	-198.13M	-195.88M	-201.14M	-190.49M
EPS	-	-	-	-	-1.35	-0.98
Free Cash Flow	-6.80M	-117.62M	-96.21M	-114.57M	-85.37M	-181.68M
No. Analysts	-	-	-	-	-	12

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	53.2M
Avg	12.9M
Low	856,000

Revenue Growth

Revenue Growth	2026	2027	2028
High	1,047.6%
Avg	179.0%
Low	-81.5%

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	-0.98
Low	-

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-